Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a, First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Anti-Fibrotic Agent PLN-74809

Next Previous
Trial Profile

A Phase 1a, First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Anti-Fibrotic Agent PLN-74809

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PLN-74809 (Primary)
  • Indications Idiopathic pulmonary fibrosis; Primary sclerosing cholangitis
  • Focus Adverse reactions; First in man
  • Sponsors Pliant Therapeutics

    • Most Recent Events

    • 09 Apr 2019 According to a Pliant Therapeutics media release, data from this trial will be presented at the American Thoracic Society International Conference 2019.
    • 09 Apr 2019 Status changed from recruiting to completed, according to the Pliant Therapeutics media release.
    • 03 Jan 2019 According to a Pliant Therapeutics media release, the first investigational new drug application for PLN-74809 was submitted based on positive preclinical studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top